FDA approves new drug Fasenra for severe asthma and rare disease.

The FDA has approved a new drug called Fasenra (benralizumab) for two conditions. First, it is an add-on maintenance treatment for severe asthma with a specific type of inflammation (eosinophilic) in people aged 6 years and older. Second, it is the first biologic approved for adults with eosinophilic granulomatosis with polyangiitis (EGPA), a rare disease that causes inflammation in blood vessels. Fasenra works by reducing the number of eosinophils, a type of white blood cell that can cause swelling and damage. It is given as an injection under the skin, and some patients may be able to self-inject after training. The approval is based on studies showing it can reduce asthma attacks and help control EGPA symptoms. However, Fasenra is not for treating sudden breathing problems or asthma attacks. Patients should continue using their rescue inhaler as needed. If you or your child has severe asthma or EGPA, talk to your doctor to see if Fasenra might be a good option. Your doctor can help you understand the benefits and risks, and decide if this treatment fits your health needs.